A 52-year-old woman with a history of leiomyoma uteri and tobacco-use disorder in remission presented with 2 months of progressive back pain. Her pain was located between her shoulder blades and was described as constant with intermittent sharp, stabbing sensation. It was nonradiating and aggravated by inspiration. She denied fever, cough, shortness of breath, chest pain, or recent changes in weight or appetite. Two days prior, she was evaluated in the ED for similar symptoms and prescribed naproxen and cyclobenzaprine for suspected musculoskeletal pain. However, she received minimal relief, which prompted her visit. She underwent a total hysterectomy 13 years ago for benign uterine fibroid tumors. She had a 15-pack-year history but quit smoking 3 years ago. Family history was notable for colon and pancreatic cancer in her father and breast cancer in her maternal aunt.

A 72-year-old man who underwent bilateral orthotropic lung transplantation for interstitial lung disease 6 months ago presented to the clinic with a 2-week history of cough, shortness of breath, and mid-back pain. The donor was negative for cytomegalovirus (CMV) and positive for Epstein-Barr virus (EBV), and the recipient was positive for both CMV and EBV. He also reported headaches but denied any fever, chills, weight loss, night sweats, chest pain, orthopnea, paroxysmal nocturnal dyspnea, or leg swelling. His other medical history included renal cell carcinoma, for which he had undergone partial right nephrectomy 6 years earlier. The patient lived in central Florida and denied any recent travel to the fungal endemic areas or international travel. He never suffered from TB or had any exposure to patients with TB. His immunosuppressive regimen consisted of tacrolimus, mycophenolate mofetil, and prednisone. The targeted tacrolimus trough level was 10 to 12 ng/mL, and the patient was generally in the therapeutic range.

A 53-year-old man was admitted with complaints of recurrent cough, mucopurulent phlegm, and fever for 10 days. These symptoms started in his youth, and he had experienced three or more acute attacks per year in the past 3 years. Persistent nasal obstruction was noticed. When asked for symptoms, the patient denied heartburn, wheezing, aspiration, night sweats, and weight loss. The patient was married for 30 years and had a son. He had never used tobacco products or alcohol. A family history indicated that his parents were consanguineously married, and one of his sisters died of bronchiectasis coinfection.

A 54-year-old Egyptian man with a 5-day history of worsening cough, high-grade fever, and progressive dyspnea was referred to our hospital. A 3-day course of ceftriaxone provided in an outpatient setting showed no clinical improvement. Medical history was unremarkable, except for bilateral pulmonary embolism diagnosed 3 years earlier. The patient actively smoked and denied the use of alcohol and illicit drugs. The patient worked as cook and had lived in Switzerland for the past 10 years. Five weeks before the actual presentation, he had traveled to Egypt. One of his children showed symptoms of a respiratory infection approximately 2 weeks before that. His only regular medication was rivaroxaban.

A 10-month-old boy with a weight of 5 kg demonstrated recurrent respiratory infections after birth, respiratory distress after feeding, and slow weight gain. At the time of presentation, he had been experiencing a cough accompanied by pyrexia for > 20 days. Prenatal ultrasound examinations revealed no abnormalities. He was born at full term via cesarean delivery and weighed 2.9 kg at birth. He was hospitalized three times because of pneumonia.

Diffuse alveolar hemorrhage (DAH) is a form of hemoptysis caused by disruption of the alveolar-capillary basement membrane causing alveolar bleeding. Inhalation of cocaine and other sympathomimetic agents are described as one of many pathologic causes. We describe what is to the author's knowledge the first reported case of DAH caused by inhalation of bupropion, a norepinephrine-dopamine reuptake inhibitor, which was successfully treated with systemic steroids. This case adds a novel agent to the known pathologic causes of DAH and introduces a novel form of bupropion toxicity, which should be considered as a cause in cases of DAH in the appropriate clinical context. The case also highlights the potential for further research into the pathologic interactions of bupropion at the alveolar basement membrane.